Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.
Recent
Upcoming
Share :

2020 Genitourinary Cancers Symposium

13 - 15 Feb 2020
Moscone West Building, San Francisco, United States of America
Videos
EV-103: Enfortumab vedotin plus pembrolizumab for locally advanced or...
Dr Jonathan Rosenberg - Memorial Sloan Kettering Cancer Center, New York, USA
EV-103: Enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma ( Dr Jonathan Rosenberg - Memorial Sloan Kettering Cancer Center, New York, USA )
19 Feb 2020
KEYNOTE 199 cohorts 4 & 5: Enzalutamide and pembrolizumab for mCRPC
Dr Julie Graff - Oregon Health & Science University, Portland, USA
KEYNOTE 199 cohorts 4 & 5: Enzalutamide and pembrolizumab for mCRPC ( Dr Julie Graff - Oregon Health & Science University, Portland, USA )
19 Feb 2020
BCG dosing for bladder cancer: Standard frequency schedule correct
Prof Oliver Grimm - Universitätsklinikum Jena, Jena, Germany
BCG dosing for bladder cancer: Standard frequency schedule correct ( Prof Oliver Grimm - Universitätsklinikum Jena, Jena, Germany )
19 Feb 2020
RADVAX: Nivolumab / ipilimumab with SBRT for metastatic renal cell carcinoma
Dr Hans Hammers - UT Southwestern Medical Center, Dallas, USA
RADVAX: Nivolumab / ipilimumab with SBRT for metastatic renal cell carcinoma ( Dr Hans Hammers - UT Southwestern Medical Center, Dallas, USA )
19 Feb 2020
CHAARTED: Luminal B subtype as a biomarker of docetaxel benefit for mHSPC
Dr Anis Hamid - Dana-Farber Cancer Institute, Boston, USA
CHAARTED: Luminal B subtype as a biomarker of docetaxel benefit for mHSPC ( Dr Anis Hamid - Dana-Farber Cancer Institute, Boston, USA )
19 Feb 2020
Integrative molecular characterisation of S/R RCC to reveal determinants of...
Dr Ziad Bakouny - Dana-Farber Cancer Institute, Boston, USA
Integrative molecular characterisation of S/R RCC to reveal determinants of poor prognosis and response to ICIs ( Dr Ziad Bakouny - Dana-Farber Cancer Institute, Boston, USA )
18 Feb 2020
Cytoreductive nephrectomy for mRCC treated with immune checkpoint inhibitors or...
Dr Ziad Bakouny - Dana-Farber Cancer Institute, Boston, USA
Cytoreductive nephrectomy for mRCC treated with immune checkpoint inhibitors or targeted therapy ( Dr Ziad Bakouny - Dana-Farber Cancer Institute, Boston, USA )
18 Feb 2020
NEO-BLADE: Nintedanib or placebo with gemcitabine and cisplatin in locally...
Dr Syed Hussain - University of Sheffield, Sheffield, United Kingdom
NEO-BLADE: Nintedanib or placebo with gemcitabine and cisplatin in locally advanced muscle invasive bladder cancer ( Dr Syed Hussain - University of Sheffield, Sheffield, United Kingdom )
18 Feb 2020
NIVOREN: Nivolumab in a 'real world setting' for metastatic clear-cell renal...
Dr Yann-Alexandre Vano - Hôpital Européen Georges-Pompidou, Paris, France
NIVOREN: Nivolumab in a 'real world setting' for metastatic clear-cell renal cell carcinoma ( Dr Yann-Alexandre Vano - Hôpital Européen Georges-Pompidou, Paris, France )
18 Feb 2020
OSPREY: PSMA-targeted PET/CT imaging in prostate cancer patients
Dr Frédéric Pouliot - Centre Hospitalier Universitaire (CHU) de Quebec
OSPREY: PSMA-targeted PET/CT imaging in prostate cancer patients ( Dr Frédéric Pouliot - Centre Hospitalier Universitaire (CHU) de Quebec )
18 Feb 2020
ASCO GU 2020: Bladder: Genomic profiling, real-world treatment challenges and...
Dr Petros Grivas, Dr Shilpa Gupta, Dr Alison Birtle and Dr Joseph Jacob
ASCO GU 2020: Bladder: Genomic profiling, real-world treatment challenges and novel agents ( Dr Petros Grivas, Dr Shilpa Gupta, Dr Alison Birtle and Dr Joseph Jacob )
14 Feb 2020
Sitravatinib and nivolumab combo for advanced clear cell renal cell cancer
Dr Pavlos Msaouel - The University of Texas MD Anderson Cancer Center, Houston...
Sitravatinib and nivolumab combo for advanced clear cell renal cell cancer ( Dr Pavlos Msaouel - The University of Texas MD Anderson Cancer Center, Houston, USA )
14 Feb 2020
BLASST-1: Combining nivolumab, gemcitabine and cisplatin for the neoadjuvant...
Dr Shilpa Gupta - Case Comprehensive Cancer Center, Cleveland, USA
BLASST-1: Combining nivolumab, gemcitabine and cisplatin for the neoadjuvant treatment of muscle invasive bladder cancer ( Dr Shilpa Gupta - Case Comprehensive Cancer Center, Cleveland, USA )
14 Feb 2020
Management of patients with advanced seminoma
Prof Peter Albers - Düsseldorf University, Düsseldorf, Germany
Management of patients with advanced seminoma ( Prof Peter Albers - Düsseldorf University, Düsseldorf, Germany )
14 Feb 2020
CHHip: Conventional versus hypofractionated high-dose intensity modulated...
Prof David Dearnaley - Institute of Cancer Research, London, UK
CHHip: Conventional versus hypofractionated high-dose intensity modulated radiotherapy for localised prostate cancer ( Prof David Dearnaley - Institute of Cancer Research, London, UK )
14 Feb 2020
Latest advances in mHSPC from ASCO GU 2020
Dr Eleni Efstathiou and Prof Axel Merseburger
Latest advances in mHSPC from ASCO GU 2020 ( Dr Eleni Efstathiou and Prof Axel Merseburger )
14 Feb 2020
ASCO GU 2020: Updates in renal cancer
Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA
ASCO GU 2020: Updates in renal cancer ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )
14 Feb 2020
Beyond p-values: When does clinical impact outweigh statistical significance?
Prof Matthew Sydes - University College London, London, UK
Beyond p-values: When does clinical impact outweigh statistical significance? ( Prof Matthew Sydes - University College London, London, UK )
14 Feb 2020
Prostate-specific membrane antigen PET: Who should undergo advanced imaging?
Dr Jérémie Calais - David Geffen School of Medicine UCLA, Los Angeles, USA
Prostate-specific membrane antigen PET: Who should undergo advanced imaging? ( Dr Jérémie Calais - David Geffen School of Medicine UCLA, Los Angeles, USA )
14 Feb 2020
Latest in prostate: Updates from TITAN, CARD and the era of personalised...
Prof Karim Fizazi, Dr Elena Castro and Prof Axel Merseburger
Latest in prostate: Updates from TITAN, CARD and the era of personalised medicine ( Prof Karim Fizazi, Dr Elena Castro and Prof Axel Merseburger )
14 Feb 2020

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation